The clinical features and outcomes of systemic AL amyloidosis: A cohort of 231 Chinese patients

Clinical Kidney Journal

Volumn 8, Issue 1, 2015, Pages 120-126

  Huang, Xianghua ^a   Wang, Qingwen ^a   Jiang, Song ^a   Chen, Wencui ^a   Zeng, Caihong ^a   Liu, Zhihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

AL amyloidosis; clinical characteristic; prognosis; risk factors

Indexed keywords

CREATININE; GLUCOSIDASE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; N ACETYL BETA DEXTRO GLUCOSIDASE; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AMYLOIDOSIS; ANEMIA; ARTICLE; BIOPSY; BONE MARROW CELL; CAUSE OF DEATH; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIALYSIS; DIARRHEA; DISEASE COURSE; DYSPNEA; EDEMA; END STAGE RENAL DISEASE; FATIGUE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PARESTHESIA; PERITONEAL DIALYSIS; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PURPURA; RECTUM BIOPSY; RISK FACTOR; SEIZURE; SEVERE RENAL IMPAIRMENT; SUBCUTANEOUS FAT; SUBCUTANEOUS FAT BIOPSY; SURVIVAL TIME; WEIGHT REDUCTION;

EID: 84928403422     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu117     Document Type: Article

References (24)

1. Cohen Ad, Comenzo Rl. Systemic Light-Chain Amyloidosis: Advances In Diagnosis, Prognosis, And Therapy. Hematology Am Soc Hematol Educ Program 2010; 2010: 287-294
2. Gertz Ma, Lacy Mq, Dispenzieri A et al. Amyloidosis. Best Pract Res Clin Haematol 2005; 18: 709-727
3. Merlini G, Bellotti V. Molecular Mechanisms Of Amyloidosis. N Engl J Med 2003; 349: 583-596
4. Comenzo Rl. Amyloidosis. Curr Treat Options Oncol 2006; 7: 225-236
5. Dember Lm. Amyloidosis-Associated Kidney Disease. J Am Soc Nephrol 2006; 17: 3458-3471
6. Kyle Ra, Gertz Ma. Primary Systemic Amyloidosis: Clinical And Laboratory Features In 474 Cases. Semin Hematol 1995; 32: 45-59
7. Falk Rh. Cardiac Amyloidosis: A Treatable Disease, Often Overlooked. Circulation 2011; 124: 1079-1085
8. Gertz Ma. Immunoglobulin Light Chain Amyloidosis: 2013 Update On Diagnosis, Prognosis, And Treatment. Am J Hematol 2013; 88: 416-425
9. Pinney Jh, Hawkins Pn. Amyloidosis. Ann Clin Biochem 2012; 49 (Pt 3): 229-241
10. Merlini G, Seldin Dc, Gertz Ma. Amyloidosis: Pathogenesis And New Therapeutic Options. J Clin Oncol 2011; 29: 1924-1933
11. Kastritis E, Dimopoulos Ma. Prognosis And Risk Assessment In Al Amyloidosis-State Of The Art. Amyloid 2011; 18 (Suppl 1): 89-91
12. Kumar S, Dispenzieri A, Katzmann Ja et al. Serum Immunoglobulin Free Light-Chain Measurement In Primary Amyloidosis: Prognostic Value And Correlations With Clinical Features. Blood 2010; 116: 5126-5129
13. Gertz Ma, Zeldenrust Sr. Treatment Of Immunoglobulin Light Chain Amyloidosis. Curr Hematol Malig Rep 2009; 4: 91-98
14. Kumar S, Dispenzieri A, Lacy Mq et al. Serum Uric Acid: Novel Prognostic Factor In Primary Systemic Amyloidosis. Mayo Clin Proc 2008; 83: 297-303
15. Gertz Ma, Lacy Mq, Dispenzieri A. Immunoglobulin Light Chain Amyloidosis And The Kidney. Kidney Int 2002; 61: 1-9
16. Kaplan B, Vidal R, Kumar A et al. Immunochemical Microanalysis Of Amyloid Proteins In Fine-Needle Aspirates Of Abdominal Fat. Am J Clin Pathol 1999; 112: 403-407
17. Dispenzieri A, Merlini G, Comenzo Rl. Amyloidosis 2008 Bmt Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant 2008; 14(Suppl 1):6-11
18. Hetzel Gr, Uhlig K, Mondry A et al. Al-Amyloidosis Of The Kidney Initially Presenting As Minimal Change Glomerulonephritis. Am J Kidney Dis 2000; 36: 630-635
19. Russo P, Palladini G, Foli A et al. Liver Involvement As The Hallmark Of Aggressive Disease In Light Chain Amyloidosis: Distinctive Clinical Features And Role Of Light Chain Type In 225 Patients. Amyloid 2011; 18 (Suppl 1): 92-93
20. Park Ma, Mueller Ps, Kyle Ra et al. Primary (Al) Hepatic Amyloidosis: Clinical Features And Natural History In 98 Patients. Medicine (Baltimore) 2003; 82: 291-298
21. Perfetti V, Colli Vignarelli M, Anesi E et al. The Degrees Of Plasma Cell Clonality And Marrow Infiltration Adversely Influence The Prognosis Of Al Amyloidosis Patients. Haematologica 1999; 84: 218-221
22. Gertz Ma, Leung N, Lacy Mq et al. Clinical Outcome Of Immunoglobulin Light Chain Amyloidosis Affecting The Kidney. Nephrol Dial Transplant 2009; 24: 3132-3137
23. Montseny Jj, Kleinknecht D, Meyrier A et al. Long-Term Outcome According To Renal Histological Lesions In 118 Patients With Monoclonal Gammopathies. Nephrol Dial Transplant 1998; 13: 1438-1445
24. Pinney Jh, Lachmann Hj, Bansi L et al. Outcome In Renal Al Amyloidosis After Chemotherapy. J Clin Oncol 2011; 29: 674-681